{"id":64415,"date":"2026-05-13T01:09:19","date_gmt":"2026-05-13T01:09:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/64415\/"},"modified":"2026-05-13T01:09:19","modified_gmt":"2026-05-13T01:09:19","slug":"roche-secures-ce-mark-for-alzheimers-blood-test","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/64415\/","title":{"rendered":"Roche secures CE mark for Alzheimer\u2019s blood test"},"content":{"rendered":"<p>Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of Alzheimer&#8217;s disease. Developed with Eli Lilly and Co., the test brings to the market another much-needed solution to help clinicians diagnose Alzheimer\u2019s patients following the FDA approval of Fujirebio Diagnostics Inc.\u2019s blood test last year.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/85-medical-technology\" rel=\"nofollow noopener\" target=\"_blank\">Medical technology<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/325-diagnostics\" rel=\"nofollow noopener\" target=\"_blank\">Diagnostics<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/256-neurology-psychiatric\" rel=\"nofollow noopener\" target=\"_blank\">Neurology\/psychiatric<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in&hellip;\n","protected":false},"author":2,"featured_media":64416,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[15909,35170,8086,3491,1176,8555,2242,197,35169,9063,20238,35168,134,473],"class_list":["post-64415","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-alzheimers-disease","tag-alzpath-inc","tag-bioworld","tag-ce-mark","tag-diagnostics","tag-elecsys","tag-eli-lilly-and-co","tag-europe","tag-fujirebio-diagnostics-inc","tag-medical-technology","tag-neurology-psychiatric","tag-ptau217","tag-roche","tag-roche-holding-ag"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116564601315145171","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=64415"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/64416"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=64415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=64415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=64415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}